NCT07027774View on ClinicalTrials.gov

Effect of Henagliflozin on Renal Outcomes in Non-dialysis Patients With Advanced Chronic Kidney Disease : A Multicenter Prospective, Randomized Controlled Trial（HERO -aCKD）

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

429

Participants

Timeline

Start Date

July 10, 2025

Primary Completion Date

December 30, 2027

Study Completion Date

December 30, 2027

Conditions
Chronic Kidney Disease Stage 4
Interventions
DRUG

Henagliflozin 5 mg Group

Henagliflozin 5 mg once daily plus KDIGO-based comprehensive management strategy (e.g., RAAS inhibitors）

DRUG

Henagliflozin 10 mg Group

Henagliflozin 10 mg once daily plus KDIGO-based comprehensive management strategy (e.g., RAAS inhibitors）

DRUG

Conventional therapy group

KDIGO-based comprehensive management strategy (e.g., RAAS inhibitors）

All Listed Sponsors
collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

First Affiliated Hospital of Wannan Medical College

OTHER